These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22534481)

  • 1. Structure-based 3D-QSAR models and dynamics analysis of novel N-benzyl pyridinone as p38α MAP kinase inhibitors for anticytokine activity.
    Ul-Haq Z; Khan W; Zia SR; Iqbal S
    J Mol Graph Model; 2012 Jun; 36():48-61. PubMed ID: 22534481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling of p38α mitogen-activated protein kinase inhibitors through 3D-QSAR and molecular dynamics simulations.
    Chang HW; Chung FS; Yang CN
    J Chem Inf Model; 2013 Jul; 53(7):1775-86. PubMed ID: 23808966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling on pyrimidine-urea inhibitors of TNF-α production: an integrated approach using a combination of molecular docking, classification techniques, and 3D-QSAR CoMSIA.
    Mouchlis VD; Melagraki G; Mavromoustakos T; Kollias G; Afantitis A
    J Chem Inf Model; 2012 Mar; 52(3):711-23. PubMed ID: 22360289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR studies of JNK1 inhibitors utilizing various alignment methods.
    Madhavan T; Chung JY; Kothandan G; Gadhe CG; Cho SJ
    Chem Biol Drug Des; 2012 Jan; 79(1):53-67. PubMed ID: 21722320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of B-RAF kinase inhibitors.
    Yang Y; Qin J; Liu H; Yao X
    J Chem Inf Model; 2011 Mar; 51(3):680-92. PubMed ID: 21338122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
    Goettert M; Schattel V; Koch P; Merfort I; Laufer S
    Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors.
    Lan P; Huang ZJ; Sun JR; Chen WM
    Int J Mol Sci; 2010 Sep; 11(9):3357-74. PubMed ID: 20957100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the binding affinity of p38α MAP kinase inhibitors by partial least squares regression.
    Basant N; Durante C; Cocchi M; Menziani MC
    Chem Biol Drug Des; 2012 Sep; 80(3):455-70. PubMed ID: 22642504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
    Ravindra GK; Achaiah G; Sastry GN
    Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
    Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
    Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
    Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
    Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode.
    Wrobleski ST; Lin S; Dhar TG; Dyckman AJ; Li T; Pitt S; Zhang R; Fan Y; Doweyko AM; Tokarski JS; Kish KF; Kiefer SE; Sack JS; Newitt JA; Witmer MR; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4120-6. PubMed ID: 23746475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dibenzepinones, dibenzoxepines and benzosuberones based p38α MAP kinase inhibitors: Their pharmacophore modelling, 3D-QSAR and docking studies.
    Khan MF; Verma G; Alam P; Akhter M; Bakht MA; Hasan SM; Shaquiquzzaman M; Alam MM
    Comput Biol Med; 2019 Jul; 110():175-185. PubMed ID: 31173941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
    Zeng H; Zhang H
    J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase.
    Jerome KD; Hepperle ME; Walker JK; Xing L; Devraj RV; Benson AG; Baldus JE; Selness SR
    Bioorg Med Chem Lett; 2010 May; 20(10):3146-9. PubMed ID: 20395140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the structural determinants of imidazole scaffold-based derivatives as p38 MAP kinase inhibitors by computational explorations.
    Huang C; Li Y; Ren H; Wang J; Shao L; Zhang S; Li G; Yang L
    Curr Med Chem; 2012; 19(23):4024-37. PubMed ID: 22680637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA.
    Gueto C; Ruiz JL; Torres JE; Méndez J; Vivas-Reyes R
    Bioorg Med Chem; 2008 Mar; 16(5):2439-47. PubMed ID: 18065233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.
    Aston NM; Bamborough P; Buckton JB; Edwards CD; Holmes DS; Jones KL; Patel VK; Smee PA; Somers DO; Vitulli G; Walker AL
    J Med Chem; 2009 Oct; 52(20):6257-69. PubMed ID: 19772287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors.
    Martz KE; Dorn A; Baur B; Schattel V; Goettert MI; Mayer-Wrangowski SC; Rauh D; Laufer SA
    J Med Chem; 2012 Sep; 55(17):7862-74. PubMed ID: 22897496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.